Showing 2401-2410 of 5696 results for "".
- Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitishttps://modernod.com/news/tarsus-completes-enrollment-for-the-pivotal-phase-3-saturn-2-trial-of-tp-03-to-treat-demodex-blepharitis/2480610/Tarsus Pharmaceuticals announced it has completed enrollment of Saturn-2, the company’s second pivotal phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for patients with Demodex blepharitis and executed a $175 million credit facility with Hercules Capital and Silicon
- Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 Granted Orphan Drug Designation by EMAhttps://modernod.com/news/neurophth-therapeutics-treatment-of-lebers-hereditary-optic-neuropathy-gene-therapy-nr082-granted-orphan-drug-designation-by-ema/2480605/Neurophth Therapeutics announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD) for the company's leading gene therapy drug candidate, NR082 (rAAV2-ND4), for the treatment of Leber's hereditary opt
- DORC Announces Strategic Partnership With WEFIS for Research and Development of Ophthalmic Instrumentshttps://modernod.com/news/dorc-announces-strategic-partnership-with-wefis-for-research-and-development-of-ophthalmic-instruments/2480584/DORC International and WEFIS GmbH have announced a strategic partnership based on an equity investment by DORC. The partnership will focus on research and development aimed at improving performance, efficiency, and usability of cataract surgery instruments. Financial terms of the d
- Johns Hopkins: Study Finds Up to 30% of Patients with Wet Macular Degeneration May Safely Stop Eye Injectionshttps://modernod.com/news/johns-hopkins-study-finds-up-to-30-of-patients-with-wet-macular-degeneration-may-safely-stop-eye-injections/2480583/In a preliminary study of 106 people with wet age-related macular degeneration (AMD), Johns Hopkins Medicine researchers report that as many as a third of those with the blinding retinal disease may someday be able to safely stop eye injection therapy without further vision loss. The fi
- Yehia Hashad, MD, to Join Bausch + Lomb as Executive Vice President of Research & Development and CMOhttps://modernod.com/news/yehia-hashad-md-will-join-bausch-lomb-as-executive-vice-president-of-research-development-and-cmo/2480581/Bausch Health Companies has announced that Yehia Hashad, MD, will join Bausch + Lomb as executive vice president of Research & Development and Chief Medical Officer (CMO), effective January 31, 2022. Dr. Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11
- AffaMed Therapeutics, licensee of Dextenza in Certain Asian Markets, Doses Their First Patient in Clinical Trial in Cataract Surgery Patientshttps://modernod.com/news/affamed-therapeutics-licensee-of-dextenza-in-certain-asian-markets-doses-their-first-patient-in-clinical-trial-in-cataract-surgery-patients/2480574/Ocular Therapeutix announced that AffaMed Therapeutics dosed its first patient in a real-world setting study being conducted in China evaluating the safety and efficacy of Dextenza (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain post-cataract surger
- NIH Researchers Develop First Stem Cell Model of Albinism to Study Related Eye Conditionshttps://modernod.com/news/nih-researchers-develop-first-stem-cell-model-of-albinism-to-study-related-eye-conditions/2480560/Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA). The model’s development is described in the January issue of the journal Stem Cell
- Regenxbio Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Deliveryhttps://modernod.com/news/regenxbio-announces-initiation-of-second-pivotal-trial-in-rgx-314-clinical-program-for-the-treatment-of-wet-amd-using-subretinal-delivery/2480556/Regenxbio announced the initiation of ASCENT, the second of two phase 3 pivotal trials to evaluate the efficacy and safety of subretinal delivery of RGX-314 in patients with wet age-related macular degeneration (AMD). ASCENT, the first trial to be initiated by Regenxbio under the e
- Ray Therapeutics Closes $6M Seed Financing to Advance Novel Optogenetics Platform to Treat Blinding Diseaseshttps://modernod.com/news/ray-therapeutics-closes-6m-seed-financing-to-advance-novel-optogenetics-platform-to-treat-blinding-diseases/2480549/Ray Therapeutics, a developer of optogenetic gene therapies for patients with blinding diseases, announced the closing of a $6 million seed financing round, led by 4BIO Capital. The funding will be used to advance its optogenetic therapy, Ray-001, into clinical trials in retinitis
- Gentex Announces Partnership With eSight To Develop Next Generation Digital Eyewearhttps://modernod.com/news/gentex-announces-partnership-with-esight-to-develop-next-generation-digital-eyewear/2480538/Gentex announced that it is partnering with eSight, provider of vision enhancement technology, to develop and manufacture the next generation of mobile electronic eyewear designed to help people living with visual impairments. Terms of the d